Stereotactic Radiotherapy and the Potential Role of Magnetic Resonance-guided Adaptive Techniques for Pancreatic Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Mar 23

PMID 35317275

Authors

Tai Ermongkonchai

Richard Khor

Vijayaragavan Muralidharan

Niall Tebbutt

Kelvin Lim

Numan Kutaiba

Sweet Ping Ng

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic cancer is a malignancy with one of the poorest prognoses amongst all cancers. Patients with unresectable tumours either receive palliative care or undergo various chemoradiotherapy regimens. Conventional techniques are often associated with acute gastrointestinal toxicities, as adjacent critical structures such as the duodenum ultimately limits delivered doses. Stereotactic body radiotherapy (SBRT) is an advanced radiation technique that delivers highly ablative radiation split into several fractions, with a steep dose fall-off outside target volumes.

Aim: To discuss the latest data on SBRT and whether there is a role for magnetic resonance-guided techniques in multimodal management of locally advanced, unresectable pancreatic cancer.

Methods: We conducted a search on multiple large databases to collate the latest records on radiotherapy techniques used to treat pancreatic cancer. Out of 1229 total records retrieved from our search, 36 studies were included in this review.

Results: Studies indicate that SBRT is associated with improved clinical efficacy and toxicity profiles compared to conventional radiotherapy techniques. Further dose escalation to the tumour with SBRT is limited by the poor soft-tissue visualisation of computed tomography imaging during radiation planning and treatment delivery. Magnetic resonance-guided techniques have been introduced to improve imaging quality, enabling treatment plan adaptation and re-optimisation before delivering each fraction.

Conclusion: Therefore, SBRT may lead to improved survival outcomes and safer toxicity profiles compared to conventional techniques, and the addition of magnetic resonance-guided techniques potentially allows dose escalation and conversion of unresectable tumours to operable cases.

Citing Articles

Daily Diagnostic Quality Computed Tomography-on-Rails (CTOR) Image Guidance for Abdominal Stereotactic Body Radiation Therapy (SBRT).

Martin-Paulpeter R, Jensen P, Perles L, Sawakuchi G, Das P, Koay E Cancers (Basel). 2024; 16(22).

PMID: 39594725 PMC: 11591933. DOI: 10.3390/cancers16223770.

Online Adaptive Radiotherapy for an Elderly Patient With Locally Advanced Pancreatic Cancer.

Jiang D, Peng J, Liu H, Wang X, Zhou F Cureus. 2024; 16(10):e71382.

PMID: 39539887 PMC: 11558018. DOI: 10.7759/cureus.71382.

Online adaptive radiotherapy in stereotactic body radiotherapy for pancreatic cancer patients.

Jiang D, Peng J, Xu H, Wang D, Xie C, Wang X Sci Rep. 2024; 14(1):22101.

PMID: 39333319 PMC: 11436912. DOI: 10.1038/s41598-024-72831-z.

New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy.

Dallavalle S, Campagnoli G, Pastena P, Martinino A, Schiliro D, Giovinazzo F Medicina (Kaunas). 2024; 60(7).

PMID: 39064499 PMC: 11278520. DOI: 10.3390/medicina60071070.

Nimbolide: A Potential Phytochemical Agent in Multimodal Pancreatic Cancer Therapies.

Jogi M, Asnani H, Singh S, Kumar P Mini Rev Med Chem. 2024; 25(1):27-41.

PMID: 38874049 DOI: 10.2174/0113895575293138240527061556.

References

Colbert L, Rebueno N, Moningi S, Beddar S, Sawakuchi G, Herman J . Dose escalation for locally advanced pancreatic cancer: How high can we go?. Adv Radiat Oncol. 2018; 3(4):693-700. PMC: 6200902. DOI: 10.1016/j.adro.2018.07.008. View

Zhong J, Patel K, Switchenko J, Cassidy R, Hall W, Gillespie T . Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017; 123(18):3486-3493. PMC: 5589506. DOI: 10.1002/cncr.30706. View

Placidi L, Romano A, Chiloiro G, Cusumano D, Boldrini L, Cellini F . On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations. Tech Innov Patient Support Radiat Oncol. 2020; 15:15-21. PMC: 7334416. DOI: 10.1016/j.tipsro.2020.06.001. View

Hammel P, Huguet F, Van Laethem J, Goldstein D, Glimelius B, Artru P . Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016; 315(17):1844-53. DOI: 10.1001/jama.2016.4324. View

Campbell W, Jones B, Schefter T, Goodman K, Miften M . An evaluation of motion mitigation techniques for pancreatic SBRT. Radiother Oncol. 2017; 124(1):168-173. PMC: 5523845. DOI: 10.1016/j.radonc.2017.05.013. View

Comito T, Cozzi L, Clerici E, Franzese C, Tozzi A, Iftode C . Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Technol Cancer Res Treat. 2016; 16(3):295-301. PMC: 5616043. DOI: 10.1177/1533034616650778. View

Dohopolski M, Glaser S, Vargo J, Balasubramani G, Beriwal S . Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer-patterns of care and overall survival. J Gastrointest Oncol. 2017; 8(5):766-777. PMC: 5674248. DOI: 10.21037/jgo.2017.08.04. View

Yechieli R, Robbins J, Mahan M, Siddiqui F, Ajlouni M . Stereotactic Body Radiotherapy for Elderly Patients With Medically Inoperable Pancreatic Cancer. Am J Clin Oncol. 2014; 40(1):22-26. DOI: 10.1097/COC.0000000000000090. View

Toesca D, Ahmed F, Kashyap M, Baclay J, von Eyben R, Pollom E . Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Radiother Oncol. 2020; 152:63-69. DOI: 10.1016/j.radonc.2020.07.053. View

10.

Vinogradskiy Y, Goodman K, Schefter T, Miften M, Jones B . The Clinical and Dosimetric Impact of Real-Time Target Tracking in Pancreatic SBRT. Int J Radiat Oncol Biol Phys. 2018; 103(1):268-275. PMC: 6596417. DOI: 10.1016/j.ijrobp.2018.08.021. View

11.

Qing S, Ju X, Cao Y, Zhang H . Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study. Radiat Oncol. 2017; 12(1):6. PMC: 5223403. DOI: 10.1186/s13014-016-0760-1. View

12.

Mazzola R, Fersino S, Aiello D, Gregucci F, Tebano U, Corradini S . Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery. Strahlenther Onkol. 2018; 194(9):835-842. DOI: 10.1007/s00066-018-1306-2. View

13.

Bohoudi O, Bruynzeel A, Meijerink M, Senan S, Slotman B, Palacios M . Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy. Radiother Oncol. 2019; 132:16-22. DOI: 10.1016/j.radonc.2018.11.019. View

14.

Jung J, Yoon S, Park J, Seo D, Lee S, Kim M . Stereotactic body radiation therapy for locally advanced pancreatic cancer. PLoS One. 2019; 14(4):e0214970. PMC: 6461258. DOI: 10.1371/journal.pone.0214970. View

15.

Park J, Hajj C, Reyngold M, Shi W, Zhang Z, Cuaron J . Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Acta Oncol. 2017; 56(12):1746-1753. DOI: 10.1080/0284186X.2017.1342863. View

16.

Luterstein E, Cao M, Lamb J, Raldow A, Low D, Steinberg M . Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach. Cureus. 2018; 10(3):e2324. PMC: 5951599. DOI: 10.7759/cureus.2324. View

17.

Heerkens H, van Vulpen M, Erickson B, Reerink O, Intven M, van den Berg C . MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer. Br J Radiol. 2018; 91(1091):20170563. PMC: 6475956. DOI: 10.1259/bjr.20170563. View

18.

Rudra S, Jiang N, Rosenberg S, Olsen J, Roach M, Wan L . Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019; 8(5):2123-2132. PMC: 6536981. DOI: 10.1002/cam4.2100. View

19.

Olberg S, Green O, Cai B, Yang D, Rodriguez V, Zhang H . Optimization of treatment planning workflow and tumor coverage during daily adaptive magnetic resonance image guided radiation therapy (MR-IGRT) of pancreatic cancer. Radiat Oncol. 2018; 13(1):51. PMC: 5866525. DOI: 10.1186/s13014-018-1000-7. View

20.

Arvold N, Niemierko A, Mamon H, Fernandez-Del Castillo C, Hong T . Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys. 2010; 80(5):1383-90. PMC: 4362517. DOI: 10.1016/j.ijrobp.2010.04.058. View